Skip to main content
  • Register
  • Help
  • Contact us

Repligen Corp (RGEN) Com Stk USD0.01

Sell:$214.85 Buy:$215.58 Change: $3.01 (1.42%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$214.85
Buy:$215.58
Change: $3.01 (1.42%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$214.85
Buy:$215.58
Change: $3.01 (1.42%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Contact details

Address:
41 Seyon St Bldg 1 Ste 100
WALTHAM
02453-8348
United States
Telephone:
+1 (781) 4499560
Website:
https://www.repligen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RGEN
ISIN:
US7599161095
Market cap:
$11.61 billion
Shares in issue:
54.77 million
Sector:
Life Sciences Tools & Services
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Karen Dawes
    Independent Chairperson of the Board
  • Anthony Hunt
    President, Chief Executive Officer, Director
  • Jon Snodgres
    Chief Financial Officer
  • Ralf Kuriyel
    Senior Vice President - Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.